Skip to Content

Qtrypta FDA Approval Status

Last updated by Judith Stewart, BPharm on Jan 21, 2020.

FDA Approved: No
Brand name: Qtrypta
Generic name: zolmitriptan
Company: Zosano Pharma Corporation
Treatment for: Migraine, Chronic Migraine

Qtrypta is a proprietary formulation of zolmitriptan that utilizes Dermally-Applied Microarray (ADAM) technology (drug-coated microneedles) in development for the acute treatment of migraine.

Development Timeline for Qtrypta

DateArticle
Oct 21, 2020Zosano Pharma Receives Complete Response Letter from FDA for Qtrypta
Mar  4, 2020Zosano Pharma Announces FDA Acceptance of 505(b)(2) New Drug Application for Qtrypta™ for the Acute Treatment of Migraine
Dec 23, 2019Zosano Announces FDA Submission of New Drug Application for Qtrypta
Nov 13, 2019Zosano Pharma Announces Completion of Pre-NDA Meetings with FDA for Qtrypta™
Feb 21, 2019Zosano Announces Completion of the Final Milestone in the Long-Term Safety Study of Qtrypta for the Acute Treatment of Migraine Disease

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.